NCT03798106View on ClinicalTrials.gov

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

August 10, 2022

Study Completion Date

August 10, 2022

Conditions
Sarcoma
Interventions
DRUG

Durvalumab, pazopanib

Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks

Trial Locations (1)

03722

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03798106 - A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter